PEP-Therapy is a pre-IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.
PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products.
Founded in January 2014, PEP-Therapy is building on research from Inserm (the French National Institute of Health), Institut Curie and Sorbonne University.
Our lead product, PEP-010, is an anti-cancer agent and is entering Phase I/II clinical trial in Q4 2020 in partnership with two leading European cancer hospitals, Institut Curie and Gustave Roussy.
PEP-Therapy raised 3.1 M€ to date from Seventure Partners (Quadrivium 1 seed fund) and a personal investment from Dr Bernard Majoie former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).
Since incorporation, PEP-Therapy has also been awarded several non-dilutive grants including a FUI grant that finances a large part of PEP-010 Phase I/II.